191 related articles for article (PubMed ID: 32458510)
1. Non-Aspergillus invasive mould infections in patients treated with ibrutinib.
Anastasopoulou A; DiPippo AJ; Kontoyiannis DP
Mycoses; 2020 Aug; 63(8):787-793. PubMed ID: 32458510
[TBL] [Abstract][Full Text] [Related]
2. [Aspergillus spondylodiscitis in a patient treated with ibrutinib].
Petitdemange A; Martin A; Ruch Y; Chatron E; Karol A; Hansmann Y
Med Mal Infect; 2020 May; 50(3):296-297. PubMed ID: 31722863
[No Abstract] [Full Text] [Related]
3. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy.
Jenks JD; Reed SL; Seidel D; Koehler P; Cornely OA; Mehta SR; Hoenigl M
Int J Antimicrob Agents; 2018 Nov; 52(5):706-712. PubMed ID: 30099056
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005-2009).
Klingspor L; Saaedi B; Ljungman P; Szakos A
Mycoses; 2015 Aug; 58(8):470-7. PubMed ID: 26152371
[TBL] [Abstract][Full Text] [Related]
5. Changes in the epidemiological landscape of invasive mould infections and disease.
Lass-Flörl C; Cuenca-Estrella M
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i5-i11. PubMed ID: 28355462
[TBL] [Abstract][Full Text] [Related]
6. Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
Booth E; Backx M; Joshi A; Nizami H; Elmusharaf N
Br J Haematol; 2023 Nov; 203(4):499-500. PubMed ID: 37696766
[No Abstract] [Full Text] [Related]
7. Emerging systemic fungal infections.
Galimberti R; Torre AC; Baztán MC; Rodriguez-Chiappetta F
Clin Dermatol; 2012; 30(6):633-50. PubMed ID: 23068151
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and risk factors for mortality of invasive non-Aspergillus mould infections in patients with haematologic diseases: A single-centre 7-year cohort study.
Lee HJ; Cho SY; Lee DG; Park C; Chun HS; Park YJ
Mycoses; 2020 Mar; 63(3):257-264. PubMed ID: 31762083
[TBL] [Abstract][Full Text] [Related]
9. Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor.
Alkharabsheh O; Alsayed A; Morlote DM; Mehta A
Curr Oncol; 2021 Feb; 28(1):837-841. PubMed ID: 33567487
[TBL] [Abstract][Full Text] [Related]
10. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
[TBL] [Abstract][Full Text] [Related]
11. Prostatic and renal aspergillosis due to Aspergillus fumigatus in a patient receiving alemtuzumab for chronic lymphocytic leukaemia.
Roux C; Thyss A; Gari-Toussaint M
J Mycol Med; 2013 Dec; 23(4):270-3. PubMed ID: 24210582
[TBL] [Abstract][Full Text] [Related]
12. Isolated central nervous system Aspergillosis infection in a chronic lymphocytic leukemia patient on Ibrutinib: A case report.
Le TH; Kumar V; Gondal K; Barnes M; Siddique H; Buttar B; Kaell A
BMC Infect Dis; 2020 Feb; 20(1):175. PubMed ID: 32093604
[TBL] [Abstract][Full Text] [Related]
13. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib.
Frei M; Aitken SL; Jain N; Thompson P; Wierda W; Kontoyiannis DP; DiPippo AJ
Leuk Lymphoma; 2020 Oct; 61(10):2488-2491. PubMed ID: 32530347
[No Abstract] [Full Text] [Related]
14. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic study of invasive fungal rhinosinusitis caused by Aspergillus and Mucorales].
He CY; Piao YS; Tian C; Li LL; Liu HG
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):662-6. PubMed ID: 23302306
[TBL] [Abstract][Full Text] [Related]
16. Study of Pathogens of Fungal Keratitis and the Sensitivity of Pathogenic Fungi to Therapeutic Agents with the Disk Diffusion Method.
Wang L; Wang L; Han L; Yin W
Curr Eye Res; 2015; 40(11):1095-101. PubMed ID: 26268399
[TBL] [Abstract][Full Text] [Related]
17. Cerebral aspergillosis in a patient on ibrutinib therapy.
Creuzet E; Nourrisson C; Chaleteix C; Poirier P; Moniot M
Br J Haematol; 2021 Jun; 193(6):1025. PubMed ID: 33748950
[No Abstract] [Full Text] [Related]
18. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
Ruchlemer R; Ben-Ami R; Bar-Meir M; Brown JR; Malphettes M; Mous R; Tonino SH; Soussain C; Barzic N; Messina JA; Jain P; Cohen R; Hill B; Mulligan SP; Nijland M; Herishanu Y; Benjamini O; Tadmor T; Okamoto K; Arthurs B; Gottesman B; Kater AP; Talha M; Eichhorst B; Korem M; Bogot N; De Boer F; Rowe JM; Lachish T
Mycoses; 2019 Dec; 62(12):1140-1147. PubMed ID: 31520441
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
[No Abstract] [Full Text] [Related]
20. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients.
Bhatti Z; Shaukat A; Almyroudis NG; Segal BH
Mycopathologia; 2006 Jul; 162(1):1-15. PubMed ID: 16830186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
